CytoPherx is developing therapies to reduce mortality among patients with acute kidney failure due to a combination of acute kidney injury, sepsis, and/or multi-organ failure.

Recent CytoPherx News

CytoPherx Named "Deal of the Year" by MVCA
CytoPherx Raises $34 Million Early Stage Venture Capital Round

Find Out More About ESP

Staff Photo

Mike Bunker led the investment in CytoPherx and joins the board